These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26143385)

  • 21. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.
    Versfeld A; McBride A; Scheibe A; Spearman CW
    Harm Reduct J; 2020 Jun; 17(1):39. PubMed ID: 32522210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel interventions to prevent HIV and HCV among persons who inject drugs.
    Coffin PO; Rowe C; Santos GM
    Curr HIV/AIDS Rep; 2015 Mar; 12(1):145-63. PubMed ID: 25589380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ;
    Int J Drug Policy; 2015 Oct; 26(10):1028-38. PubMed ID: 26282715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.
    Auriacombe M; Roux P; Briand Madrid L; Kirchherr S; Kervran C; Chauvin C; Gutowski M; Denis C; Carrieri MP; Lalanne L; Jauffret-Roustide M;
    BMJ Open; 2019 Feb; 9(2):e023683. PubMed ID: 30796121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
    Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
    Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.
    Hickman M; De Angelis D; Vickerman P; Hutchinson S; Martin NK
    Curr Opin Infect Dis; 2015 Dec; 28(6):576-82. PubMed ID: 26524330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
    Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
    J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs.
    Høj SB; Jacka B; Minoyan N; Artenie AA; Bruneau J
    Int J Drug Policy; 2019 Oct; 72():11-23. PubMed ID: 31003825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.
    Walsh N; Maher L
    Curr Opin HIV AIDS; 2012 Jul; 7(4):339-44. PubMed ID: 22498482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global policy and access to new hepatitis C therapies for people who inject drugs.
    Doyle JS; Aspinall EJ; Hutchinson SJ; Quinn B; Gore C; Wiktor SZ; Hellard ME
    Int J Drug Policy; 2015 Nov; 26(11):1064-71. PubMed ID: 26118794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
    J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.